Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.57 |
| ▸ | GSK3A | P49840 | 5/20 | 0.57 |
| ▸ | AURKA | O14965 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.56 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422211 | 0.84 | MEN1 (0.67) | GSK3BGSK3AAURKAMAPTMEN1 | |
| SCHEMBL5511597 | 0.82 | PTK2 (0.50) | AURKAMEN1KMT2APTK2LRRK2 | |
| SCHEMBL5417264 | 0.81 | GSK3B (0.59) | GSK3BGSK3AAURKAMAPTMEN1 | |
| SCHEMBL5408359 | 0.80 | MAPT (0.86) | GSK3BGSK3AAURKAMAPTMEN1 | |
| SCHEMBL5409960 | 0.79 | MEN1 (0.60) | GSK3BGSK3AAURKAMAPTMEN1 | |
| SCHEMBL5416097 | 0.79 | GSK3B (0.54) | GSK3BGSK3AAURKAMAPTMEN1 | |
| SCHEMBL5419368 | 0.79 | GSK3B (0.63) | GSK3BGSK3AAURKAMAPTMEN1 | |
| SCHEMBL5413779 | 0.79 | GSK3B (0.60) | GSK3BGSK3AAURKAMAPTMEN1 | |
| SCHEMBL5407967 | 0.78 | GSK3B (0.59) | GSK3BGSK3AAURKAMAPTMEN1 | |
| SCHEMBL5408207 | 0.78 | GSK3B (0.61) | GSK3BGSK3AAURKAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1703405-A | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-30 | — | — | CN | claimed |
| CN-100436427-C | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-26 | — | — | CN | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| CN-1703405-A | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-30 | — | — | CN | disclosed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | disclosed |
| CN-1373763-A | Pteridinones and kinase inhibitors | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | CN | disclosed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | GSK3B 414/4885GSK3A 529/4885AURKA 142/4885 |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | CCNI, CCNK, CDK2 | GSK3B 631/4885GSK3A 872/4885AURKA 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.